secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261663
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q3 net loss $33.1M; XPOVIO revenue up 8.5%; SENTRY data March 2026
-----------------------------------------------------------------------------

- Total rev $44.0M ($38.8M Q3 2024); U.S. XPOVIO net product rev $32.0M (+8.5% vs $29.5M).
- Net loss $33.1M ($3.82/sh) vs $32.1M ($3.85/sh); operating loss improved 42% to $15.2M.
- Phase 3 SENTRY myelofibrosis trial enrollment complete (353 pts); top-line data due March 2026.
- Reaffirms FY2025 total rev guidance $140M-$155M, XPOVIO rev $110M-$120M; lowers expense guide to $235M-$245M.
- Cash $46.2M at Sep 30 (proforma ~$78M after Oct 8 financing); expects liquidity into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/0001193125-25-261663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/kpti-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer